𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of combination therapy with amantadine, thymosin α1 and α/β interferon in mice infected with influenza a virus

✍ Scribed by Cartesio D'Agostini; Anna Teresa Palamara; Cartesio Favalli; Mariliana Sivilia; Giuseppe Febbraro; Cristina Bue; Enrico Garaci

Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
616 KB
Volume
18
Category
Article
ISSN
0192-0561

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Long-term outcomes of thymosin-α1 and in
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and

Efficacy of low-dose intermittent interf
Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

## Abstract The efficacy of interferon (IFN) monotherapy for non‐responders to pegylated interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy is still unclear. To evaluate the impact of IFN monotherapy on biochemical response, 200 consecutive patients infected with HCV genotype 1b, who rec

A mutation in the interferon sensitivity
A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b
✍ Mutsumi Murayama; Yoshiaki Katano; Isao Nakano; Masatoshi Ishigami; Kazuhiko Hay 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 2 views

## Abstract The interferon sensitivity‐determining region (ISDR) is useful as a predictive marker of the response to interferon (IFN) therapy for chronic hepatitis patients with a Japan‐specific subtype (J‐type) of hepatitis C virus (HCV) genotype 1b. This marker is not useful for predicting respon

A randomized controlled trial of thymosi
A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B
✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission